Skip to content

Therapeutic Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy

Research output: Contribution to journalBook/Film/Article review

Original languageEnglish
Article number2
Number of pages10
JournalCurrent Neurology and Neuroscience Reports
Issue number1
Early online date14 Jan 2019
DateAccepted/In press - 3 Jan 2019
DateE-pub ahead of print - 14 Jan 2019
DatePublished (current) - Jan 2019


Purpose of Review Therapeutic hypothermia reduces death or disability in term and near-term infants with moderate-severe
hypoxic-ischemic encephalopathy. Nevertheless, many infants still survive with disability, despite hypothermia, supporting
further research in to ways to further improve neurologic outcomes.
Recent Findings Recent clinical and experimental studies have refined our understanding of the key parameters for hypothermic
neuroprotection, including timing of initiation, depth, and duration of hypothermia, and subsequent rewarming rate. However,
important knowledge gaps remain. There is encouraging clinical evidence from a small phase II trial that combined treatment of
hypothermia with recombinant erythropoietin further reduces risk of disability but definitive studies are still needed.
Summary In conclusion, recent studies suggest that current protocols for therapeutic hypothermia are near-optimal, and that the
key to better neurodevelopmental outcomes is earlier diagnosis and initiation of hypothermia after birth. Further research is
essential to find and evaluate ways to further improve outcomes after hypoxic-ischemic encephalopathy, including add-on
therapies for therapeutic hypothermia and preventing pyrexia during labor and delivery.

    Research areas

  • Neonatal encephalopathy, Therapeutic hypothermia, Neonatal neuroprotection, Fetal sheep, Erythropoietin, Neonatal examination



  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Springer Nature at Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 336 KB, PDF document

    Embargo ends: 14/01/20

    Request copy


View research connections

Related faculties, schools or groups